POSFREA
Live / Registered — Registered (as of 23 Sept 2025)
What this means for you
Registered since 23 Sept 2025. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 23 Sept 2031: the §8 declaration of use).
Record
- Serial number
- 98355367
- Registration number
- 7962039
- Mark type
- Word mark
- Filed
- 12 Jan 2024
- Published for opposition
- 24 Sept 2024
- Registered
- 23 Sept 2025
- Next maintenance filing
- §8 declaration of use, due by 23 Sept 2031 (grace period to 23 Mar 2032)
- Attorney of record
- R. Scott Keller
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the prevention of nausea and vomiting in cancer treatment and following a surgical treatment
Owner
- Avyxa Pharma LLC, Parsippany, NJ, US
- Avyxa Pharma LLC, Parsippany, NJ, US
- Avyxa Pharma LLC, Parsippany, NJ, US
Prosecution history
- 23 Sept 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 23 Sept 2025 — REGISTERED-PRINCIPAL REGISTER
- 03 Sept 2025 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 02 Sept 2025 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 12 Aug 2025 — STATEMENT OF USE PROCESSING COMPLETE
- 25 Nov 2024 — USE AMENDMENT FILED
- 12 Aug 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 25 Nov 2024 — TEAS STATEMENT OF USE RECEIVED
- 19 Nov 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 24 Sept 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 24 Sept 2024 — PUBLISHED FOR OPPOSITION
- 04 Sept 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 16 Aug 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 08 Aug 2024 — ASSIGNED TO EXAMINER
- 06 May 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED